House allergic alveolitis

Summary

House allergic alveolitis (MONDO:0020535) is a disease. A subtype of hypersensitivity pneumonitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	house allergic alveolitis
Mondo ID	MONDO:0020535
Orphanet	99907
ICD-11	1985023223
SNOMED CT	725415009
UMLS	C4511048
MedGen	1387737
GARD	0019703
Is cancer (heuristic)	no

Disease family

This is a subtype of hypersensitivity pneumonitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › allergic respiratory disease › hypersensitivity pneumonitis › house allergic alveolitis

Related subtypes (13): ventilation pneumonitis, bagassosis, farmer’s lung disease, malt worker’s lung, cork-handlers’ disease, maple bark strippers’ lung, bird fancier’s lung, mushroom workers’ lung, sick building syndrome, hypersensitivity pneumonitis, familial, idiopathic chronic eosinophilic pneumonia, non-fibrotic hypersensitivity pneumonitis, fibrotic hypersensitivity pneumonitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.